Compliance Containment Insulin 
The Pharma Data
JUNE 29, 2021
New Soliqua ® * data shows improved blood sugar control without weight gain versus premixed insulin. Study also shows more people on Soliqua had improved blood sugar control without weight gain and without low blood sugar events (hypoglycemia) in first head-to-head comparison with premixed insulin.
XTalks
JUNE 5, 2023
Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 31, 2022
Alongside fitness trackers and smartwatches, there are also medical devices used to monitor a patient’s vitals and some even contain SIM cards to enable two-way communication. Alongside obtaining consent, any organisation dealing with patient data must also ensure compliance with the necessary regulations.
XTalks
JULY 15, 2021
The test involves the use of testing strips that contain a glucose biosensor with electronic elements in the test’s transistor, like inks, that allow for mass printing of the test strips at low cost. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market. Biosensor Technology.
The Pharma Data
NOVEMBER 30, 2020
The simplification transaction will reduce the Company’s tax compliance costs, enhance its ability to structure future acquisitions and result in the Class A Common Stock being the Company’s only class of Common Stock outstanding. Accordingly, undue reliance should not be placed upon the forward-looking statements.
FDA Law Blog
DECEMBER 3, 2023
The manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug. At a minimum, the manufacturer’s agreement must cover all its labeler codes that contain an applicable drug or a selected drug, and update CMS within 3 business days of being assigned a new labeler code.
The Pharma Data
AUGUST 3, 2021
The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk. The company announced positive top-line results from the SURPASS-4 Phase 3 clinical trial of tirzepatide in adults with type 2 diabetes, evaluating A1C and body weight reductions from baseline. 25% $ 2,988.1 $ 2,459.1
Expert insights. Personalized for you.
52 
Let's personalize your content